Our Science
Every tumor has a signature. Xenagos Finds It.
Opportunity to leverage cancer's own high precision targeting strategy.
The Problem
Antibody-Based Targeting Therapiesare constrained.
Very few tumor-enriched targets leave a single point of failure for multiple therapeutic classes.
AntibodyPayload
LinkerCytotoxin
LinkerCytotoxinAntibody-drug conjugates use antigens that are over-expressed on cancer cells to enrich the tumor with toxin
The Solution
Xenagos is leveraging cancer's ownhigh precision targeting strategy.
XenaGuides are tumor-targeted sequences that can deliver anti-cancer payloads.
Encoded
Development-linked sequences are active during embryogenesis and tissue lineage formation
Silenced
After embryogenesis, these sequences are silenced to preserve genomic stability in healthy tissues
Reawakened
Cancer reactivates these tissue-specific sequences and sheds them as ctDNA, creating unique biological signatures
Mobilized
ctDNA can carry transferable genetic information, including resistance traits, between cancer cells in a tissue- and tumor-specific manner
Exploited
Because ctDNA sequences are tissue- and tumor-specific, their selectivity can be co-opted for highly precise payload delivery in the XenaGuide Platform
How We Work
Tumor specific by nature.Broadly applicable by design.
Naturally Derived
XenaGuides (XGs) are identified from naturally circulating ctDNA sequences, meaning their safety profile is de-risked.
Tumor Selective, Not Patient Selective
Screened against diverse patient datasets, tumor-specific receptor uptake of XGs ensures diminished off target effects of even the most toxic payloads without the complexity of personalized medicine.
Targeted Payload Delivery
XGs are designed to deliver anti-cancer therapies in a payload-agnostic manner.
Evidence Standards
XenaGuides SelectivelyDeliver Payloads to Tumor
In Vitro, In Vivo, and Ex Vivo Evidence of Tumor Targeting
ctDNA
Universe of millions of DNA sequences, a subset of which are targeted
XenaGuides
Single, isolated sequence selected for exquisitely specific payload delivery
Xenagos has three levels of evidence demonstrating tumor specific targeting
In vitro
Across multiple susceptible and resistant cell lines.
In vivo
Across both cell and patient derived xenograft models.
Ex vivo
Within patient-derived primary tissue.
Learn more about our precision oncology strategy and platform capabilities by connecting with our team.
Contact UsOperating Model
Key Benefits of the XenagosXenaGuide Platform
Highly Specific Targeting
Highly specific targeting leveraging cancer's native biology.
Expanded Oncology Toolkit
Novel platform expands the oncology toolkit.
Payload Compatibility
Compatible with a variety of payloads.
Scalable Manufacturing
Scalable manufacturing with more flexibility and more precise drug loading than antibodies.
Partnership Opportunities
Multiple partnering opportunities in parallel to lead product development.